R&D Reconfiguring COVID and influenza vaccines for long-term eff... Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company's breakthrough vaccine technology, oligoDOM, and how it's driving the development of new influenza and SARS-CoV-2 vacc
News Moderna jab on trial for cancer-causing syndrome Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
